سعر اراسيتين 100مجم/5مل فيال 2022

Aracytin (Pfizer) is cytarabine (cytosine arabinoside, Ara-C) 100 mg per 5 ml vial for injection, a pyrimidine-analogue antimetabolite antineoplastic used mainly for remission induction in acute myeloid (non-lymphoblastic) leukaemia, given IV or SC under specialist oncology supervision.

• Induction of remission in acute myeloid (non-lymphoblastic) leukaemia in adults and children.Population: Adults and childrenMediately (reproduction of the AIFA-authorised Italian RCP)
• Other proliferative disorders of the white blood cell series (secondary indication).Population: Adults and childrenMediately (reproduction of the AIFA-authorised Italian RCP)
• UK licensed uses: induction of remission in acute myeloid leukaemia in adults and other acute leukaemias of adults and children (acute non-lymphoblastic, acute lymphoblastic, erythroleukaemia, blast crisis of CML), high-grade non-Hodgkin lymphoma, and intrathecal treatment of meningeal leukaemia/neoplasms.Population: Adults and childrenElectronic medicines compendium (emc)

• Myelosuppression (leucopenia, thrombocytopenia, anaemia, megaloblastosis) is the principal toxicity. Very common/common: anorexia, nausea, vomiting, diarrhoea, oral/anal inflammation or ulceration, hepatic dysfunction, fever, rash, alopecia, thrombophlebitis at injection site, and cytarabine syndrome. Less common: sepsis, pneumonia, pancreatitis, oesophagitis, bowel necrosis, neuritis/neurotoxicity, conjunctivitis, anaphylaxis.International label, equivalent formulation · Electronic medicines compendium (emc)

• Hypersensitivity to cytarabine or any excipient; pre-existing drug-induced bone-marrow suppression unless the physician judges it the most promising option; degenerative and toxic encephalopathies, especially after methotrexate or ionising radiation.International label, same formulation · Mediately (reproduction of the AIFA-authorised Italian RCP)
• Hypersensitivity to cytarabine; anaemia, leucopenia and thrombocytopenia of non-malignant aetiology (e.g. bone-marrow aplasia) unless benefit outweighs risk; degenerative and toxic encephalopathies.International label, equivalent formulation · Electronic medicines compendium (emc)
• Known hypersensitivity to cytarabine.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• BOXED WARNING (US): only physicians experienced in cancer chemotherapy should use cytarabine; induction therapy should be given in a facility with laboratory and supportive resources. The main toxicity is dose-related bone-marrow suppression (leucopenia, thrombocytopenia, anaemia); less serious toxicity includes nausea, vomiting, diarrhoea, abdominal pain, oral ulceration and hepatic dysfunction.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Potent bone-marrow suppressant: monitor leucocyte and platelet counts daily during induction and bone-marrow examinations after blast clearance; suspend or modify therapy when platelets fall below 50,000/mm3 or polymorphonuclear granulocytes below 1,000/mm3; facilities to manage infections and bleeding must be available.International label, same formulation · Mediately (reproduction of the AIFA-authorised Italian RCP)
• Anaphylactic reactions (including fatal cardiopulmonary arrest) have occurred. High-dose regimens (2-3 g/m2) can cause severe and sometimes fatal CNS, GI and pulmonary toxicity (cerebellar dysfunction, severe GI ulceration, pneumatosis, necrotising colitis, sepsis, liver abscess, pulmonary oedema/ARDS, cardiomyopathy). Pancreatitis, hyperuricaemia from rapid lysis (monitor uric acid; consider allopurinol and hydration) and neurological reactions with concomitant intrathecal methotrexate may occur. Avoid live vaccines in immunocompromised patients. Use with caution and at reduced dose in hepatic or renal impairment.International label, same formulation · Mediately (reproduction of the AIFA-authorised Italian RCP)

• Digoxin (beta-acetyldigoxin tablets)Reversible decrease in steady-state digoxin plasma levels and renal glycoside excretion with combination chemotherapy including cytarabine; monitor digoxin levels (digitoxin may be an alternative).Mediately (reproduction of the AIFA-authorised Italian RCP)
• GentamicinIn vitro antagonism of gentamicin activity against K. pneumoniae; patients on cytarabine treated with gentamicin for K. pneumoniae sepsis without a rapid response may need re-evaluation of antibacterial therapy.Mediately (reproduction of the AIFA-authorised Italian RCP)
• Flucytosine (5-fluorocytosine)Cytarabine may inhibit the efficacy of flucytosine (competitive inhibition of its uptake).Mediately (reproduction of the AIFA-authorised Italian RCP)

• Cytarabine is teratogenic in animals; congenital anomalies (upper and lower limbs, ears) have been reported after first-trimester exposure, and neonatal pancytopenia, leucopenia and other effects after exposure later in pregnancy. Do not use in confirmed or suspected pregnancy unless clearly necessary; women of child-bearing potential should use effective contraception during and for 6 months after treatment, and men with partners of child-bearing potential for 3 months after treatment.International label, same formulation · Mediately (reproduction of the AIFA-authorised Italian RCP)
• Cytarabine can cause fetal harm when administered to a pregnant woman; advise of the potential risk to a fetus.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Breast-feeding should be discontinued during treatment and for at least one week after the last dose.International label, same formulation · Mediately (reproduction of the AIFA-authorised Italian RCP)

• Cytarabine: Cell-cycle (S-phase) specific antimetabolite: converted intracellularly to cytarabine triphosphate, which inhibits DNA polymerase and is incorporated into DNA, blocking DNA synthesis in dividing cells.